Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference

Rhea-AI Summary

Grace Therapeutics (Nasdaq: GRCE) announced that CEO Prashant Kohli will present at the Craig-Hallum 16th Annual Alpha Select Conference on November 18, 2025 in New York.

Grace is a late-stage biopharma advancing GTx-104, an injectable nimodipine formulation for IV infusion to treat aneurysmal subarachnoid hemorrhage (aSAH) patients. The Alpha Select Conference is invitation-only; attending companies are selected for being smaller, underfollowed public companies with potential to scale. Investors seeking a meeting should contact their Craig-Hallum representative.

News Market Reaction

-1.96%

1 alert

-1.96% News Effect

On the day this news was published, GRCE declined 1.96%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

PRINCETON, N.J., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that Chief Executive Officer Prashant Kohli will participate/present in the upcoming Craig-Hallum 16th Annual Alpha Select Conference, to be held Tuesday, November 18, 2025 in New York, NY.

Companies attending the Alpha Select Conference have been individually selected by the Craig-Hallum research team and are either currently on or display characteristics that are consistent with the Alpha Select List—an actively researched collection of smaller, underfollowed public companies that Craig-Hallum believes have the potential to become much larger. The Alpha Select list typically consists of sub-$500M market cap companies with attractive business models, above average growth trends, favorable macro-secular themes, and management teams that Craig-Hallum believes can take the business to the next level.

The Alpha Select Conference is invitation only. To request a meeting with Mr. Kohli, please contact your Craig-Hallum representative.

About aneurysmal Subarachnoid Hemorrhage (aSAH)

aSAH is bleeding over the surface of the brain in the subarachnoid space between the brain and the skull, which contains blood vessels that supply the brain. A primary cause of such bleeding is the rupture of an aneurysm in the brain. The result is a relatively uncommon type of stroke (aSAH) that accounts for about 5% of all strokes and an estimated 42,500 U.S. hospital treated patients.

About GTx-104

GTx-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for I.V. infusion in aSAH patients to address significant unmet medical needs. The unique nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral I.V. infusion. GTx-104 provides a convenient I.V. delivery of nimodipine in the Intensive Care Unit, potentially eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Intravenous delivery of GTx-104 also has the potential to lower food effects, drug-to-drug interactions, and eliminate potential dosing errors. Further, GTx-104 has the potential to better manage hypotension in aSAH patients. GTx-104 has been administered in over 200 patients and healthy volunteers and was well tolerated with significantly lower inter- and intra-subject pharmacokinetic variability compared to oral nimodipine.

About Grace Therapeutics

Grace Therapeutics, Inc. (Grace Therapeutics or the Company) is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Grace Therapeutics’ novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery. Grace Therapeutic’s lead clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection with over 40 granted and pending patents. Grace Therapeutics’ lead clinical asset, GTx-104, is an I.V. infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull.

For more information, please visit: www.gracetx.com

For more information, please contact:

Grace Therapeutics Contact:

Prashant Kohli
Chief Executive Officer
Tel: 450-686-4555
Email: info@gracetx.com
www.gracetx.com

Investor Relations:

LifeSci Advisors
Mike Moyer
Managing Director
Phone: 617-308-4306
Email: mmoyer@lifesciadvisors.com

FAQ

When will Grace Therapeutics (GRCE) present at the Craig-Hallum Alpha Select Conference?

CEO Prashant Kohli will present on November 18, 2025 in New York.

What program will Grace Therapeutics discuss at the November 18, 2025 presentation?

The company is advancing GTx-104, an injectable nimodipine IV infusion for aSAH patients.

How can investors request a meeting with Grace Therapeutics (GRCE) at the Alpha Select Conference?

Investors should contact their Craig-Hallum representative to request a meeting with Mr. Kohli.

What type of companies attend the Craig-Hallum Alpha Select Conference?

The conference features invitation-only, typically sub-$500M market cap companies selected for growth potential.

Will Grace Therapeutics release new clinical data at the November 18, 2025 presentation?

The announcement only confirms CEO participation; no specific clinical data release was stated.